Intermittent Hypoxia Selects for Genotypes and Phenotypes That Increase Survival, Invasion, and Therapy Resistance
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Hypoxia in tumors correlates with greater risk of metastases, increased invasiveness, and resistance to systemic and radiation therapy. The evolutionary dynamics that links specific adaptations to hypoxia with these observed tumor properties have not been well investigated. While some tumor populations may experience fixed hypoxia, cyclical and stochastic transitions from normoxia to hypoxia are commonly observed in vivo. Although some phenotypic adaptations to this cyclic hypoxia are likely reversible, we hypothesize that some adaptations may become fixed through mutations promoted by hypoxia-induced genomic instability. Here we seek to identify genetic alterations and corresponding stable phenotypes that emerge following cyclic hypoxia. Although these changes may originate as adaptations to this specific environmental stress, their fixation in the tumor genome may result in their observation in tumors from regions of normoxia, a condition known as pseudohypoxia. We exposed several epithelial cell lines to 50 cycles of hypoxia-normoxia, followed by culture in normoxia over a period of several months. Molecular analyses demonstrated permanent changes in expression of several oncogenes and tumor-suppressors, including p53, E-cadherin, and Hif-1α. These changes were associated with increased resistance to multiple cytotoxins, increased survival in hypoxia and increased anchorage-independent growth. These results suggest cycles of hypoxia encountered in early cancers can select for specific and stable genotypic and phenotypic properties that persist even in normoxic conditions, which may promote tumor progression and resistance to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168 · cited 1×
“The process of carcinogenesis is speculated to occur during a decades-long period [47, 48].”
BackgroundDistant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300 · cited 3×
“In vitro studies have shown that hypoxia selects for cells carrying mutations in p53 such that minor populations engineered to carry nonfunctional alleles of TP53 eventually overtake populations wild-type for TP53 [11], which can lead to apoptosis resistance.”
BackgroundIntratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Sottoriva, A., Spiteri, I., Piccirillo, S. G. M., Touloumis, A., Collins, V. P., Marioni, J. C., Curtis, C., Watts, C., & Tavaré, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219747110 · Cited by 1,737
Direct regulation of TWIST by HIF-1α promotes metastasis
Yang, M.-H., Wu, M.-Z., Chiou, S.-H., Chen, P.-M., Chang, S.-Y., Liu, C.-J., Teng, S.-C., & Wu, K.-J. (2008) · Nature Cell Biology · doi:10.1038/ncb1691 · Cited by 1,345
Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J. K. V., Markowitz, S., Zhou, S., et al. (2009) · Science · doi:10.1126/science.1174229 · Cited by 914
Overview of resistance to systemic therapy in patients with breast cancer
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904
Hypoxia-regulated target genes implicated in tumor metastasis
Tsai, Y.-P., & Wu, K.-J. (2012) · Journal of Biomedical Science · doi:10.1186/1423-0127-19-102 · Cited by 190 · cited 5×
“The epithelial-to-mesenchymal transition (EMT) is the process by which cells lose their epithelial characteristics and become more migratory.”
Influential
Research works printed but not linked: 50
- D Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
- RA Gatenby, 2008, A microenvironmental model of carcinogenesis, Nature reviews, 8, 56
- GH Fletcher, 1984, Radiation and drug resistance of breast cancer, Am J Clin Oncol, 7, 617, 10.1097/00000421-198412000-00007 · DOI
- J Zhou, 2006, Tumor hypoxia and cancer progression, Cancer Lett, 237, 10, 10.1016/j.canlet.2005.05.028 · DOI · Paper page
- M Hockel, 2001, Biological consequences of tumor hypoxia, Biological consequences of tumor hypoxia, 28, 36
- CA Aktipis, 2011, Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research, PLOS One, 6, e26100, 10.1371/journal.pone.0026100 · DOI
- JW Wojtkowiak, 2011, Drug resistance and cellular adaptation to tumor acidic pH microenvironment, Mol Pharm, 8, 2032, 10.1021/mp200292c · DOI · Paper page
- S Cardaci, 2012, TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State, International journal of cell biology, 2012, 161837, 10.1155/2012/161837 · DOI · Paper page
- MG Cattaneo, 2011, Chronic deficiency of nitric oxide affects hypoxia inducible factor-1alpha (HIF-1alpha) stability and migration in human endothelial cells, PLOS One, 6, e29680, 10.1371/journal.pone.0029680 · DOI
- RS Bindra, 2005, Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis, Mutat Res, 569, 75, 10.1016/j.mrfmmm.2004.03.013 · DOI · Paper page
- M Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, 366, 883, 10.1056/NEJMoa1113205 · DOI · Paper page
- C Bayer, 2012, Acute versus chronic hypoxia in tumors: Controversial data concerning time frames and biological consequences, Strahlenther Onkol, 188, 616, 10.1007/s00066-012-0085-4 · DOI
- CC Wykoff, 2000, Hypoxia-inducible expression of tumor-associated carbonic anhydrases, Cancer Res, 60, 7075
- R Airley, 2001, Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix, Clin Cancer Res, 7, 928
- G Helmlinger, 1997, Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation, Nature medicine, 3, 177, 10.1038/nm0297-177 · DOI · Paper page
- MW Dewhirst, 1996, Microvascular studies on the origins of perfusion-limited hypoxia, Br J Cancer Suppl, 27, S247
- RD Braun, 1999, Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats, Am J Physiol, 277, H551
- C Baudelet, 2006, The role of vessel maturation and vessel functionality in spontaneous fluctuations of T2*-weighted GRE signal within tumors, NMR in biomedicine, 19, 69, 10.1002/nbm.1002 · DOI · Paper page
- A Gilead, 1999, Dynamic remodeling of the vascular bed precedes tumor growth: MLS ovarian carcinoma spheroids implanted in nude mice, Neoplasia, 1, 226, 10.1038/sj.neo.7900032 · DOI · Paper page
- RS Bindra, 2007, Regulation of DNA repair in hypoxic cancer cells, Cancer Metastasis Rev, 26, 249, 10.1007/s10555-007-9061-3 · DOI · Paper page
- AX Meng, 2005, Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells, Radiother Oncol, 76, 168, 10.1016/j.radonc.2005.06.025 · DOI · Paper page
- SD Young, 1988, Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells, Proc Natl Acad Sci U S A, 85, 9533, 10.1073/pnas.85.24.9533 · DOI · Paper page
- AE Greijer, 2004, The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis, J Clin Pathol, 57, 1009, 10.1136/jcp.2003.015032 · DOI · Paper page
- MT Santore, 2002, Anoxia-induced apoptosis occurs through a mitochondria-dependent pathway in lung epithelial cells, Am J Physiol Lung Cell Mol Physiol, 282, L727, 10.1152/ajplung.00281.2001 · DOI
- RJ Gillies, 2012, Evolutionary dynamics of carcinogenesis and why targeted therapy does not work, Nature reviews, 12, 487
- IM Pires, 2010, Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability, Cancer Res, 70, 925, 10.1158/0008-5472.CAN-09-2715 · DOI · Paper page
- JP Piret, 2006, Hypoxia protects HepG2 cells against etoposide-induced apoptosis via a HIF-1-independent pathway, Exp Cell Res, 312, 2908, 10.1016/j.yexcr.2006.05.018 · DOI
- JP Cosse, 2007, Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines, Mol Cancer, 6, 61, 10.1186/1476-4598-6-61 · DOI
- GC Rice, 1986, Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells, Proc Natl Acad Sci U S A, 83, 5978, 10.1073/pnas.83.16.5978 · DOI · Paper page
- D Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 · DOI · Paper page
- F Nollet, 1999, The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer, Mol Cell Biol Res Commun, 2, 77, 10.1006/mcbr.1999.0155 · DOI · Paper page
- M Kadota, 2010, Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines, PLOS One, 5, e9201, 10.1371/journal.pone.0009201 · DOI · Paper page
- JW Wojtkowiak, 2012, Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments, Cancer Res, 72, 3938, 10.1158/0008-5472.CAN-11-3881 · DOI · Paper page
- M Brazdova, 2013, Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells, PLOS One, 8, e59567, 10.1371/journal.pone.0059567 · DOI · Paper page
- F Vikhanskaya, 2005, Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs, Clin Cancer Res, 11, 4348, 10.1158/1078-0432.CCR-04-1547 · DOI · Paper page
- JD Storey, 2003, Statistical significance for genomewide studies, Proc Natl Acad Sci U S A, 100, 9440, 10.1073/pnas.1530509100 · DOI · Paper page
- DG Ginzinger, 2000, Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis, Cancer Res, 60, 5405
- RA Gatenby, 2004, Why do cancers have high aerobic glycolysis?, Nature reviews, 4, 891
- S Yachida, 2013, Evolution and dynamics of pancreatic cancer progression, Oncogene, 18, 29
- RJ Gillies, 2008, Causes and consequences of increased glucose metabolism of cancers, J Nucl Med, 49, 24S, 10.2967/jnumed.107.047258 · DOI · Paper page
- MW Dewhirst, 2007, Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting, Cancer Res, 67, 854, 10.1158/0008-5472.CAN-06-4744 · DOI · Paper page
- A Giatromanolaki, 2001, Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer, Cancer Res, 61, 7992
- SK Chia, 2001, Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma, J Clin Oncol, 19, 3660, 10.1200/JCO.2001.19.16.3660 · DOI · Paper page
- D Generali, 2006, Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer, Clin Cancer Res, 12, 4562, 10.1158/1078-0432.CCR-05-2690 · DOI · Paper page
- AM Jubb, 2010, Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis, J Cell Mol Med, 14, 18, 10.1111/j.1582-4934.2009.00944.x · DOI · Paper page
- RJ Gillies, 2007, Hypoxia and adaptive landscapes in the evolution of carcinogenesis, Cancer Metastasis Rev, 26, 311, 10.1007/s10555-007-9065-z · DOI · Paper page
- RA Gatenby, 2007, Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer, Br J Cancer, 97, 646, 10.1038/sj.bjc.6603922 · DOI · Paper page
- A Ibrahim-Hashim, 2012, Systemic buffers inhibit carcinogenesis in TRAMP mice, J Urol, 188, 624, 10.1016/j.juro.2012.03.113 · DOI
- KM Bailey, 2012, Targeting the metabolic microenvironment of tumors, Adv Pharmacol, 65, 63, 10.1016/B978-0-12-397927-8.00004-X · DOI · Paper page
- RA Gatenby, 2010, Evolutionary dynamics of cancer prevention, Nature reviews, 10, 526
Cited by
Classifying the evolutionary and ecological features of neoplasms
Maley, C. C., Aktipis, A., Graham, T. A., Sottoriva, A., Boddy, A. M., Janiszewska, M., Silva, A. S., Gerlinger, M., Yuan, Y., Pienta, K. J., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.69 · Cited by 423
Self-citationSystems analysis of intracellular pH vulnerabilities for cancer therapy
Persi, E., Duran-Frigola, M., Damaghi, M., Roush, W. R., Aloy, P., Cleveland, J. L., Gillies, R. J., & Ruppin, E. (2018) · Nature Communications · doi:10.1038/s41467-018-05261-x · Cited by 406
Self-citationSpatial Heterogeneity in the Tumor Microenvironment
Yuan, Y. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026583 · Cited by 342
Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy
Dunne, M., Regenold, M., & Allen, C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.007 · Cited by 150
Liu, L., Liu, W., Wang, L., Zhu, T., Zhong, J., & Xie, N. (2017) · Oncology Letters · doi:10.3892/ol.2017.7223 · Cited by 42
Metadata
- Authors
- Verduzco, D., Lloyd, M., Xu, L., Ibrahim-Hashim, A., Balagurunathan, Y., Gatenby, R. A., & Gillies, R. J.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-03-26
- Volume
- 10
- Issue
- 3
- Pages
- e0120958
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2010469141
- Cited by
- 75
- References
- 9
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.